Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
|Videos|August 18, 2022
Psilocybin: The Complicated Conversation
Author(s)John J. Miller, MD
The resistance against "magic mushrooms"—is it justified?
Advertisement
John J. Miller, MD, tries to untangle the controversies around psilocybin in this video and in his talk at the
Dr Miller is Medical Director, Brain Health, Exeter, New Hampshire; Editor in Chief, Psychiatric Times™; Staff Psychiatrist, Seacoast Mental Health Center, Exeter; Consulting Psychiatrist, Exeter Hospital, Exeter; Consulting Psychiatrist, Insight Meditation Society, Barre, Massachusetts.
Advertisement
Related to this article
Atypical psychedelics such as ketamine, MDMA, and ibogaine show fast-acting promise for depression, PTSD, and addiction beyond 5-HT2A.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.
FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.
Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.
Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.
Psychedelic psilocybin therapy shows year-long relief in treatment-resistant depression, with strong response rates and stable safety.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
2
Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder
3
New Analyses of HLP003 for the Adjunctive Treatment of MDD
4
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
5